Towards Healthcare
Branded Generics Market to Surge USD 867.21 Bn by 2035

Branded Generics Market Boosted by Demand for Affordable Therapies

Market insights predict, the branded generics industry is expected to grow from USD 383.1 billion in 2025 to USD 867.21 billion by 2035, driven by a CAGR of 8.47%. The branded generics market is growing due to the rising prevalence of chronic health conditions has increased demand for long-term drug therapies. North America is leading due to the strong presence of a robust healthcare infrastructure and increasing investment through the government.

Content

  • Last Updated: 05 November 2025
  • Report Covered: [Revenue + Volume]
  • Historical Year: 2021-2023
  • Base Year: 2024
  • Estimated Years: 2025-2034

About The Author

Shivani Zoting is a dedicated research analyst specializing in the healthcare industry. With a strong academic foundation, a B.Sc. in Biotechnology and an MBA in Pharmabiotechnology, she brings a unique blend of scientific understanding and market strategy to her research.

Shivani contributes to Towards Healthcare and plays an active role at Precedence Research, where she focuses on delivering in-depth market intelligence, competitive analysis, and trend forecasting across pharmaceuticals, medical devices, digital health, and healthcare services. Her insights support healthcare companies, investors, and policymakers in making data-backed decisions in a highly regulated and rapidly evolving sector.

Additionally, Shivani collaborates with Statifacts, further expanding her healthcare domain reach by engaging in diverse projects across global markets. Her strength lies in transforming complex clinical and commercial data into strategic narratives that help stakeholders navigate the future of healthcare.

Talk to us
FAQ's

The branded generics market holds a valuation of USD 415.54 billion as of 2026, and will expand to USD 867.21 billion by 2035, achieving a CAGR of 8.47% between 2025 and 2035.

North America is currently leading the branded generics market share by 38% due to high healthcare spending and government policies encouraging generic substitution.

The branded generics market includes six segments by product type, by dosage form, by application, by therapeutic area, by distribution channel, by end user, and by region.

Key trends include government initiatives and regulatory support that favor cost-effective alternatives.

Generics work as well as their brand-name siblings, often costing considerably less. The reason for the variation in cost is not because of lower quality, but because research and advertising costs for the generics are much lower than the original cost for the brand-name drug.

Ministry of Health and Family Welfare, Government of India, National Institutes of Health, FDA, WHO, PIB, CDC.
Any Questions